Form 4: Galectin Therapeutics Director Exercises, Sells Shares
Statement of Changes in Beneficial Ownership
A director at Galectin Therapeutics Inc. executed pre-planned option exercises and subsequent share sales in December 2025.
Summary
- Harold H. Shlevin, a Director of Galectin Therapeutics Inc. (GALT), reported transactions involving the exercise of stock options and the sale of common stock.
- On December 12, 2025, Mr. Shlevin exercised 19,793 stock options at an exercise price of $4.16 per share and subsequently sold 19,793 common shares at a weighted average price of $6.274 per share.
- On December 15, 2025, Mr. Shlevin exercised an additional 8,417 stock options at an exercise price of $4.16 per share and sold 8,417 common shares at a weighted average price of $6.30 per share.
- All reported transactions were conducted pursuant to a Rule 10b5-1 plan adopted by Mr. Shlevin on August 29, 2025.
- Following these transactions, Mr. Shlevin directly beneficially owns 11,206 shares of common stock.
- After all reported exercises, Mr. Shlevin beneficially owns 45,000 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The sentiment is neutral. While the director profited from the sale, it was a pre-scheduled transaction under a 10b5-1 plan, which typically reduces the market's interpretation of the sale as a signal of negative sentiment towards the company's future prospects. It's a routine insider disclosure.
Positives
- The director realized a profit from the transactions, selling shares at an average price significantly higher than the exercise price ($6.274 and $6.30 vs. $4.16).
- The transactions were executed under a pre-arranged Rule 10b5-1 plan, indicating a structured approach to insider trading rather than opportunistic timing.
Negatives
- The director reduced their direct beneficial ownership of common stock by selling all shares acquired through the option exercises, which could be perceived as a reduction in direct stake in the company.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance from the company or its management.
Industry Context
This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape for Galectin Therapeutics Inc.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Adoption of Trading Plan | The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, and disclosed in the Issuer’s Quarterly Report on Form 10-Q filed on November 14, 2025. | 08/29/2025 | A Rule 10b5-1 plan allows insiders to set up a pre-arranged schedule for buying or selling company stock, providing an affirmative defense against insider trading allegations. This enhances transparency and reduces the perception of opportunistic trading. |
Stakeholder Impact
- Shareholders: The transactions represent a reduction in the director's direct common stock ownership, though it was a pre-planned event. The director retains a significant number of stock options.
Key Dates
| Date | Description |
|---|---|
| 06/30/2018 | 25% of the stock options vested. |
| 09/30/2018 | Another 25% of the stock options vested. |
| 12/31/2018 | The remaining 50% of the stock options vested. |
| 08/29/2025 | Rule 10b5-1 plan adopted by the reporting person. |
| 11/14/2025 | Issuer's Quarterly Report on Form 10-Q filed, disclosing the Rule 10b5-1 plan. |
| 12/12/2025 | Exercise of 19,793 stock options and sale of 19,793 common shares. |
| 12/15/2025 | Exercise of 8,417 stock options and sale of 8,417 common shares. |
| 12/16/2025 | Date of signature for the Form 4 filing. |
| 05/22/2028 | Expiration date of the stock options. |
Keywords
Galectin Therapeutics, GALT, Insider Trading, Form 4, Stock Options, Share Sale, Director Transaction, Rule 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.